In vitro activity of antifungals against Zygomycetes

被引：62

作者：

Alastruey-Izquierdo, A. ^{[1
]}

Castelli, M. V. ^{[1
]}

Cuesta, I. ^{[1
]}

Zaragoza, O. ^{[1
]}

Monzon, A. ^{[1
]}

Mellado, E. ^{[1
]}

Rodriguez-Tudela, J. L. ^{[1
]}

机构：

[1] Inst Salud Carlos III, Mycol Reference Lab, Serv Micol, Natl Ctr Microbiol, Madrid 28220, Spain

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2009年 / 15卷

关键词：

Antifungal; in vitro activity; mucormycosis; Zygomycetes; CUNNINGHAMELLA-BERTHOLLETIAE INFECTION; LIPOSOMAL AMPHOTERICIN-B; MURINE PULMONARY MUCORMYCOSIS; INVASIVE FUNGAL-INFECTIONS; RHINOCEREBRAL MUCORMYCOSIS; SALVAGE THERAPY; DISSEMINATED ZYGOMYCOSIS; INOCULUM PREPARATION; ABSIDIA-CORYMBIFERA; LIPID COMPLEX;

D O I：

10.1111/j.1469-0691.2009.02984.x

中图分类号：

R51 [传染病];

学科分类号：

100201 [内科学];

摘要：

P>To date, no reference standard for therapy for zygomycosis has been established because there are insufficient clinical data with which to make such a judgement. Knowledge of the species responsible for the infection and its antifungal susceptibility profile has become increasingly important in the management of patients. Amphotericin B is the most active drug against all the species involved, followed by posaconazole, whereas voriconazole has no activity. Echinocandins are completely inactive in vitro, but may be an interesting option when used in combination with other drugs.

引用

页码：71 / 76

页数：6

共 64 条

[1]

Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi [J].

Aberkane, A ;

Cuenca-Estrella, M ;

Gomez-Lopez, A ;

Petrikkou, E ;

Mellado, E ;

Monzón, A ;

Rodriguez-Tudela, JL .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) :719-722

[2]

In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents [J].

Almyroudis, Nikolaos G. ;

Sutton, Deanna A. ;

Fothergill, Annette W. ;

Rinaldi, Michael G. ;

Kusne, Shimon .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (07) :2587-2590

[3]

Posaconazole prophylaxis in experimental systemic zygomycosis [J].

Barchiesi, Francesco ;

Spreghini, Elisabetta ;

Santinelli, Alfredo ;

Fothergill, Annette W. ;

Pisa, Eleonora ;

Giannini, Daniele ;

Rinaldi, Michael G. ;

Scalise, Giorgio .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (01) :73-77

[4]

Belfiori R, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-46

[5]

BUTALA A, 1995, J NATL MED ASSOC, V87, P572

[6]

Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery:: a case report [J].

Çagatay, AA ;

Öncü, SS ;

Çalangu, SS ;

Yildirmak, TT ;

Özsüt, HH ;

Eraksoy, HH .

BMC INFECTIOUS DISEASES, 2001, 1 (1)

[7]

Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. [J].

Chryssanthou, E. ;

Cuenca-Estrella, M. .

CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 (09) :901-904

[8]

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi [J].

Cuenca-Estrella, M ;

Gomez-Lopez, A ;

Mellado, E ;

Buitrago, MJ ;

Monzon, A ;

Rodriguez-Tudela, JL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :917-921

[9]

In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents [J].

Dannaoui, E ;

Afeltra, J ;

Meis, JFGM ;

Verweij, PE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2708-2711

[10]

Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis [J].

Dannaoui, E ;

Mouton, JW ;

Meis, JFGM ;

Verweij, PE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1953-1959

← 1 2 3 4 5 6 7 →